|Bid||88.26 x 1300|
|Ask||88.27 x 800|
|Day's Range||88.07 - 88.77|
|52 Week Range||76.41 - 88.83|
|PE Ratio (TTM)||38.89|
|Earnings Date||Aug 21, 2018|
|Forward Dividend & Yield||2.00 (2.26%)|
|1y Target Est||94.60|
Three multinational companies have received an Israeli government grant of 120 million shekels ($33 million) aimed at boosting the presence of large companies and establishing Israel as a hub in biotechnology and medicine. The grants are part of a new programme to boost the field of digital health, inject new intellectual property in Israel, which is expected to generate significant future tax income, and establish a long-term presence for multinational firms. The companies chosen to participate in the programme are medical device firm Medtronic, GE Healthcare, a unit of General Electric, and Change Healthcare, a supplier of digital health solutions.
On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Masimo Corp. (NASDAQ: MASI), Medtronic PLC (NYSE: MDT), and MiMedx Group Inc. (NASDAQ: MDXG).
Rating Action: Moody's assigns B2 CFR to MedPlast Holdings, Inc. New York, July 17, 2018 -- Moody's Investors Service ("Moody's) assigned a B2 Corporate Family Rating (CFR) and B2-PD Probability of Default Rating to MedPlast Holdings, Inc. ("MedPlast"). Moody's also assigned a B1 rating to the company's first lien credit facilities comprised of a $70 million revolving credit facility and a $500 million first lien term loan and a Caa1 rating to the company's $225 million second lien term loan.
July 12, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) labeling expansion for the Medtronic SelectSecure(TM) MRI SureScan(TM) Model 3830 cardiac pacing lead to include stimulation of the bundle of His. The steroid-eluting, bipolar SelectSecure SureScan MRI model 3830 lead (lengths of 59, 69 and 74 cm) is attached to a single or dual chamber pacemaker, and approved for pacing and sensing in the atrium, right ventricle, or at the bundle of His as an alternative to right ventricular pacing. Lead placement at or near the bundle of His can be facilitated by the Medtronic C315HIS delivery catheter.
Medtronic said it received FDA approval for a less-invasive implant approach of its HVAD System, a left ventricular assist device for patients with advanced heart failure.
July 11, 2018 - Medtronic plc (MDT) has received United States Food and Drug Administration (FDA) approval for a less-invasive implant approach of its HVAD(TM) System, a left ventricular assist device (LVAD) for patients with advanced heart failure. The HVAD System is the smallest commercially available LVAD, and the only LVAD approved in the U.S. for implant via thoracotomy, a small lateral, surgical incision between the patient`s ribs on the left side of the chest.
BRAMPTON, ON, July 11, 2018 /CNW/ - Medtronic of Canada Ltd., a subsidiary of Medtronic plc (MDT), today announced the StealthStation™ S8 and the StealthStation™ ENT (Ear, Nose and Throat) surgical navigation systems are now licensed for sale in Canada . Surgeons use surgical navigation systems to help with precisely locating anatomical structures and instruments in either open or minimally invasive procedures on rigid parts of the body like the skull and vertebra, as well as sinus cavities. Both platforms are now commercially available in Canada .
July 10, 2018 - Medtronic plc (MDT) and UnitedHealthcare today announced first year results from an innovative value-based relationship focused on delivering patient-centered solutions that improve health outcomes while reducing soaring healthcare costs related to managing diabetes. Results from an analysis of over 6,000 members with diabetes on Medtronic MiniMed(TM) 630G and previous generation insulin pumps demonstrated 27 percent fewer preventable hospital admissions compared to plan participants who are on multiple daily injections of insulin (MDI).
Evercore ISI analyst Vijay Kumar has named Becton, Dickinson and Co. The three months ended June 30, BD's third fiscal quarter for 2018, is the "first clean [quarter] without any adjustments for US dispensing change / flu noise," Kumar wrote in a note on Monday, July 9. Franklin Lakes, N.J.-based BD is scheduled to release results on Aug. 2.
Medtronic (MDT) continues to meaningfully accelerate all its three fundamental growth strategies, namely therapy innovation, globalization and economic value.
Polaris, 58.com, BlackRock, Intuitive Surgical, Medtronic and NuVasive as Zacks Bull and Bear of the Day
Medical device stocks and the related ETFs are among the brightest spots in the broader healthcare sector this year. iShares U.S. Medical Devices ETF (NYSEArca: IHI), the largest dedicated medical devices ...
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Applied ...
The United States has hit rough waters of late. Rising trade war tensions between the United States and China are showing no signs of abatement. The issue has escalated to a point where imposition of tariffs and retaliatory tariffs may go up to $450 billion on both the sides.
DUBLIN- June 28, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced the launch of the MiniMed(TM) 670G Performance Guarantee Program - an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this Guarantee, Medtronic will provide flat-fee reimbursements up to $25,000 per pump over 4 years for qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States. "This new program demonstrates the strong confidence we have in our ability to deliver improved clinical outcomes with our MiniMed670G system and our commitment to value-based healthcare that not only improves outcomes but drives down the enormous burden of diabetes-related healthcare costs," said Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic.
In fiscal Q4 2018, Medtronic’s (MDT) Diabetes segment generated revenue of $645 million compared to $512 million in fiscal 2017, which reflected a ~26% rise YoY (year-over-year).
In fiscal Q4 2018, Medtronic’s (MDT) restorative spine therapies business generated revenue of $699 million compared to $676 million in fiscal Q4 2017, a rise of ~3% YoY (year-over-year).
In fiscal Q4 2018, Medtronic’s (MDT) Restorative Therapies Group segment reported revenue of $2.1 billion compared to $1.95 billion in fiscal Q4 2017, which reflected a ~9% YoY (year-over-year) rise.
Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the second quarter.